Loading stock data…
RADX
$4.41+0.14 (+3.28%)
Market ClosedLast close May 1
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Radiopharm Theranostics Limited in the Healthcare sector is trading at $4.41. The stock is currently near its 52-week low of $3.62, remaining 14.7% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why RADX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.41
Potential Upside
5%
Whystock Fair Value$4.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$18.07+309.7%
Range$13.06 – $31.06
Fundamentals
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops sever...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$36.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.07%
Volume
Today's trading volume
32,909
Recent News
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference
Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term clinical catalysts during a presentation at the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference. Chief Executive Officer Riccardo Canevari described the compa
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
Radiopharm Theranostics ADR (NASDAQ:RADX) is among the best Australian stocks to buy in 2026. Radiopharm Theranostics ADR (NASDAQ:RADX) continues to advance its clinical programs with solid results. On April 20, the company presented initial findings from an early-stage trial of its cancer drug candidate at the American Association for Cancer Research Annual Meeting. The drug […]
Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase 1 clinical trial of its lead prostate cancer candidate RAD 402, marking the company’s entry into first-in-human studies for the program. The trial is evaluating RAD 402 in patients with...
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study
Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company’s ongoing Phase IIb study of RAD101, a PET imaging tracer intended to help physicians evaluate suspected recurrent brain metastases after radiotherapy when MRI results are un
Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks
Radiopharm Theranostics (NASDAQ:RADX) provided an update on its clinical-stage radiopharmaceutical pipeline during an investor conference presentation led by CEO Riccardo Canevari, highlighting interim results from its lead imaging program and progress across four therapeutic candidates in human tri